ArticleEndocrine2025
Neuroendocrine tumors in patients with inflammatory bowel disease: a case series.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe incidence of inflammatory bowel diseases (IBDs) and gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) has increased, but their potential association remains unclear. Chronic inflammation in IBD may contribute to enteroendocrine cell hyperplasia and neoplasia, though evidence for a causal link is limited. This case series describes the characteristics and outcomes of patients with coexisting IBD and GEP-NETs at a tertiary referral center.
methodsRetrospective case series including all consecutive IBD patients who were referred to the IBD Unit at the IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy, between January 2019 and December 2024 and who had been diagnosed with a GEP-NET.
resultsNine Crohn’s disease patients (44.4% female, mean IBD diagnosis age: 51.1 years) also had GEP-NETs. The median interval between IBD and GEP-NET diagnoses was 39.3 months (0-180). In the totality of six cases that underwent surgical intervention, NETs diagnosis was incidental on the surgical specimen. Lesion sites included ileum (3), appendix (3), stomach (2), and rectum (1). Most NETs were G1 (88.8%); one required somatostatin analogues due to metastases. Treatments included surgery (6), endoscopy (2), and one pending. Over a median 24-month follow-up, no recurrences or disease-related deaths occurred. No cases of ulcerative colitis and concomitant GEP-NET ‘s diagnosis were observed in the patient cohort under consideration.
conclusionsPatients with Crohn’s disease may have a higher prevalence of GEP-NETs, possibly due to chronic inflammation and immune/microbiota dysregulation. This association does not appear to worsen disease outcomes. Larger studies are needed to explore underlying mechanisms.
Indexed as
Identifiers
41091298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.